[The use of the cephalosporin antibiotic Zinnat under polyclinic conditions in treating patients with bronchopulmonary infections]. / Primenenie tsefalosporinovogo antibiotika zinnata v poliklinicheskikh usloviiakh pri lechenii bol'nykh s bronkholegochnymi infektsiiami.

The cephalosporin antibiotic zinnat was given to 171 outpatients with bronchopulmonary infections. Pneumonia patients received 500 mg, patients with acute bronchitis or exacerbation of chronic bronchitis 250 mg twice a day. The recovery was registered in 97.7, 98.8 and 91.8% of patients, respectively. The drug proved effective, low-toxic, convenient in use. Wide-spectrum action, significant activity against both gram-positive and gram-negative pathogens make zinnat a promising drug for outpatient treatment of bronchopulmonary infections.

[A comparative study of the expression of activation markers on T-lymphocyte subpopulations in different forms of bronchial asthma]. / Sravnitel'noe izuchenie ékspressii markerov aktivatsii na subpopuliatsiiakh T-limfotsitov pri razlichnykh formakh bronkhial'noi astmy.

In this study we investigated a phenotype of intact and PHA-stimulated T-lymphocytes from peripheral blood of patients with allergic and nonallergic asthma. Expression of the activation markers (CD25, CD71, HLA-DR) on subsets of T-lymphocytes (CD4+ and CD8+) was determined using double-colour flow cytometry. It was found that nonallergic patients had increased percentages of CD4+CD25+, CD8+CD25+, CD4+HLA-DR+, CD8+HLA-DR+ cells. Allergic patients had a significant increase of CD4+CD25+ cells only. To examine functional significance of these changes mononuclear cells were cultivated with PHA in vitro. Thus, our findings improve our knowledge about asthma pathogenesis and create the grounds for pathogenetically validated immunocorrection.